StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Alnylam Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.56B, up 24.9% year over year. For fiscal 2025 it was $1.32B, up 17.2% from the year before. Over ten years it grew 16.9% a year on average. The highest annual figure on record is $1.32B in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.32B+17.2%
FY2024Dec 31, 2024$1.13B+12.1%
FY2023Dec 31, 2023$1.00B+13.7%
FY2022Dec 31, 2022$883.02M+11.5%
FY2021Dec 31, 2021$792.16M+21.0%
FY2020Dec 31, 2020$654.82M-0.0%
FY2019Dec 31, 2019$655.11M+29.6%
FY2018Dec 31, 2018$505.42M+29.4%
FY2017Dec 31, 2017$390.64M+2.2%
FY2016Dec 31, 2016$382.39M+38.3%
FY2015Dec 31, 2015$276.50M+45.3%
FY2014Dec 31, 2014$190.25M+68.4%
FY2013Dec 31, 2013$112.96M+30.5%
FY2012Dec 31, 2012$86.57M-12.8%
FY2011Dec 31, 2011$99.30M-6.7%
FY2010Dec 31, 2010$106.38M-2.2%
FY2009Dec 31, 2009$108.73M+12.2%
FY2008Dec 31, 2008$96.88M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$408.54M+13.9%
Q2 FY2026Jun 30, 2026$413.13M+27.7%
Q1 FY2026Mar 31, 2026$364.87M+37.6%
Q4 FY2025Dec 31, 2025$372.22M+24.0%
Q3 FY2025Sep 30, 2025$358.81M+32.4%
Q2 FY2025Jun 30, 2025$323.62M+10.0%
Q1 FY2025Mar 31, 2025$265.12M+1.6%
Q4 FY2024Dec 31, 2024$300.17M+10.3%
Q3 FY2024Sep 30, 2024$270.93M+7.0%
Q2 FY2024Jun 30, 2024$294.14M+18.4%
Q1 FY2024Mar 31, 2024$261.00M+13.2%
Q4 FY2023Dec 31, 2023$272.14M+3.9%
Q3 FY2023Sep 30, 2023$253.18M+3.2%
Q2 FY2023Jun 30, 2023$248.53M+20.8%
Q1 FY2023Mar 31, 2023$230.57M+35.7%
Q4 FY2022Dec 31, 2022$262.04M+14.4%
Q3 FY2022Sep 30, 2022$245.37M+26.1%
Q2 FY2022Jun 30, 2022$205.71M+12.6%
Q1 FY2022Mar 31, 2022$169.89M-8.6%
Q4 FY2021Dec 31, 2021$229.05M+36.0%
Q3 FY2021Sep 30, 2021$194.57M+20.3%
Q2 FY2021Jun 30, 2021$182.64M+17.8%
Q1 FY2021Mar 31, 2021$185.90M+9.6%
Q4 FY2020Dec 31, 2020$168.47M-16.3%
Q3 FY2020Sep 30, 2020$161.78M+0.6%
Q2 FY2020Jun 30, 2020$155.00M-5.4%
Q1 FY2020Mar 31, 2020$169.57M+31.3%
Q4 FY2019Dec 31, 2019$201.30M+53.6%
Q3 FY2019Sep 30, 2019$160.80M+14.9%
Q2 FY2019Jun 30, 2019$163.89M+19.1%
Q1 FY2019Mar 31, 2019$129.13M+33.3%
Q4 FY2018Dec 31, 2018$131.04M+11.3%
Q3 FY2018Sep 30, 2018$139.95M+46.9%
Q2 FY2018Jun 30, 2018$137.58M+51.8%
Q1 FY2018Mar 31, 2018$96.86M+11.4%
Q4 FY2017Dec 31, 2017$117.77M+12.2%
Q3 FY2017Sep 30, 2017$95.25M–
Q2 FY2017Jun 30, 2017$90.63M–
Q1 FY2017Mar 31, 2017$86.98M–
Q4 FY2016Dec 31, 2016$105.01M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?